A sensitive venous bleeding model in haemophilia A mice: effects of two recombinant FVIII products (N8 and Advate(®)). (Q45878529)

17 December 2017

title

A sensitive venous bleeding model in haemophilia A mice: effects of two recombinant FVIII products (N8 and Advate(®)). (English)

1 reference

17 December 2017

0 references

0 references

A E Pastoft

1

1 reference

17 December 2017

J Lykkesfeldt

2

1 reference

17 December 2017

M Ezban

3

1 reference

17 December 2017

M Tranholm

4

1 reference

17 December 2017

H C Whinna

5

1 reference

17 December 2017

B Lauritzen

6

1 reference

17 December 2017

publication date

16 April 2012

1 reference

17 December 2017

published in

Haemophilia

1 reference

17 December 2017

volume

18

1 reference

17 December 2017

issue

5

1 reference

17 December 2017

page(s)

782-788

1 reference

17 December 2017

Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

Optimization, refinement and reduction of murine in vivo experiments to assess therapeutic approaches for haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

A ferric chloride induced arterial injury model used as haemostatic effect model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

Experimental haemophilic synovitis: rationale and development of a murine model of human factor VIII deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

Strategies towards a longer acting factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

Functional characteristics of N8, a new recombinant FVIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

Purification and characterization of a new recombinant factor VIII (N8).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII-based clots

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

Rat model of arterial thrombosis induced by ferric chloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

Pathogenesis of haemophilic arthropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

Prevention of haemarthrosis in a murine model of acute joint bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2012.02780.X

10.1111/J.1365-2516.2012.02780.X

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017